Analysts expect ConforMIS, Inc. (NASDAQ:CFMS) to post sales of $17.69 million for the current quarter, Zacks Investment Research reports. Five analysts have made estimates for ConforMIS’s earnings, with estimates ranging from $17.29 million to $18.00 million. ConforMIS posted sales of $18.64 million in the same quarter last year, which suggests a negative year over year growth rate of 5.1%. The business is expected to issue its next earnings results on Thursday, November 2nd.

On average, analysts expect that ConforMIS will report full-year sales of $17.69 million for the current year, with estimates ranging from $75.79 million to $77.14 million. For the next fiscal year, analysts forecast that the company will report sales of $83.55 million per share, with estimates ranging from $81.35 million to $85.74 million. Zacks’ sales averages are a mean average based on a survey of research analysts that that provide coverage for ConforMIS.

ConforMIS (NASDAQ:CFMS) last issued its quarterly earnings data on Thursday, August 3rd. The medical instruments supplier reported ($0.28) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.36) by $0.08. ConforMIS had a negative return on equity of 66.61% and a negative net margin of 72.87%. The business had revenue of $18.50 million for the quarter, compared to the consensus estimate of $19.34 million. During the same period last year, the business earned ($0.34) EPS. The firm’s revenue was down 4.1% compared to the same quarter last year.

Several research analysts recently commented on the company. BTIG Research reissued a “hold” rating on shares of ConforMIS in a research report on Sunday, July 16th. Zacks Investment Research raised ConforMIS from a “sell” rating to a “buy” rating and set a $4.75 price target for the company in a research report on Wednesday, July 12th. Oppenheimer Holdings, Inc. set a $6.00 price target on ConforMIS and gave the company a “buy” rating in a research report on Friday, August 4th. Deutsche Bank AG reissued a “hold” rating and set a $5.00 price target (down from $6.00) on shares of ConforMIS in a research report on Friday, August 4th. Finally, ValuEngine raised ConforMIS from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and three have issued a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $6.71.

A number of large investors have recently added to or reduced their stakes in CFMS. Teachers Advisors LLC raised its stake in ConforMIS by 27.6% in the fourth quarter. Teachers Advisors LLC now owns 73,565 shares of the medical instruments supplier’s stock valued at $596,000 after buying an additional 15,890 shares during the period. Wells Fargo & Company MN raised its stake in ConforMIS by 1.8% in the first quarter. Wells Fargo & Company MN now owns 53,930 shares of the medical instruments supplier’s stock valued at $282,000 after buying an additional 935 shares during the period. American International Group Inc. raised its stake in ConforMIS by 7.0% in the first quarter. American International Group Inc. now owns 22,009 shares of the medical instruments supplier’s stock valued at $115,000 after buying an additional 1,448 shares during the period. Wellington Management Group LLP raised its stake in ConforMIS by 2.4% in the first quarter. Wellington Management Group LLP now owns 5,644,206 shares of the medical instruments supplier’s stock valued at $29,463,000 after buying an additional 132,211 shares during the period. Finally, Geode Capital Management LLC raised its stake in ConforMIS by 4.4% in the first quarter. Geode Capital Management LLC now owns 329,058 shares of the medical instruments supplier’s stock valued at $1,717,000 after buying an additional 13,731 shares during the period. Hedge funds and other institutional investors own 33.60% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this article on another domain, it was copied illegally and republished in violation of United States and international trademark and copyright law. The correct version of this article can be read at https://www.thecerbatgem.com/2017/09/30/17-69-million-in-sales-expected-for-conformis-inc-cfms-this-quarter.html.

ConforMIS (NASDAQ:CFMS) opened at 3.52 on Friday. ConforMIS has a 52 week low of $3.50 and a 52 week high of $10.93. The company’s market capitalization is $157.82 million. The company has a 50 day moving average price of $3.74 and a 200-day moving average price of $3.74.

ConforMIS Company Profile

ConforMIS, Inc is a medical technology company. The Company uses its iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants, which are individually sized and shaped, to fit each patient’s anatomy. The Company’s iFit technology platform is applicable to various joints.

Get a free copy of the Zacks research report on ConforMIS (CFMS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ConforMIS (NASDAQ:CFMS)

Receive News & Stock Ratings for ConforMIS Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ConforMIS Inc. and related stocks with our FREE daily email newsletter.